Clover Biopharmaceuticals lands $43 mln Series B

China-based Clover Biopharmaceuticals, a clinical-stage biotechnology company, has raised $43 million in Series B financing.

China-based Clover Biopharmaceuticals, a clinical-stage biotechnology company, has raised $43 million in Series B financing. Delos Capital and Lapam Capital led the round with participation from Betta Capital, Sichuan Health Care Industry Fund, Beijing Zhongguancun VC and Jinlong Group. BFC Group was financial adviser to Clover on the transaction.

Source: Press Release